

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/002522

International filing date: 26 January 2005 (26.01.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/626,678
Filing date: 09 November 2004 (09.11.2004)

Date of receipt at the International Bureau: 31 March 2005 (31.03.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1299001

UNITED STATES OF AMERICA

TO ALL, TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

March 21, 2005


THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A
FILING DATE.

APPLICATION NUMBER: 60/626,678

FILING DATE: *November 09, 2004*

RELATED PCT APPLICATION NUMBER: PCT/US05/02522

Certified by



Under Secretary of Commerce
for Intellectual Property
and Director of the United States
Patent and Trademark Office



110904
21861 U.S.P.T.O.17548 U.S.P.T.O.
60/626678

110904

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. EV 520328363US

INVENTOR(S)

Given Name (first and middle [if any]) Family Name or Surname Residence
(City and either State or Foreign Country)

Shawn DeFrees North Wales, PA

Zhi-Guang Wang Dresher, PA

 Additional inventors are being named on the separately numbered sheets attached hereto

TITLE OF THE INVENTION (500 characters max)

GLYCOLIPIDS

Direct all correspondence to: CORRESPONDENCE ADDRESS

 Customer Number

043850

OR

 Firm or
Individual Name

Address

Address

City

State

ZIP

Country

Telephone

Fax

ENCLOSED APPLICATION PARTS (check all that apply)

 Specification Number of Pages

51

 CD(s), Number Drawing(s) Number of Sheets Other (specify) Application Data Sheet. See 37 CFR 1.76

METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT

 Applicant claims small entity status. See 37 CFR 1.27. A check or money order is enclosed to cover the filing feesFILING FEE
Amount (\$) The Director is hereby authorized to charge filing
fees or credit any overpayment to Deposit Account Number: 50-0310
Payment by credit card. Form PTO-2038 is attached.

80.00

The invention was made by an agency of the United States Government or under a contract with an agency of the
United States Government. No. Yes, the name of the U.S. Government agency and the Government contract number are: .

[Page 1 of 2]

Date 11/09/04

Respectfully submitted,



SIGNATURE

REGISTRATION NO. 46,690

TYPED or PRINTED NAME Todd Esker

(if appropriate)

TELEPHONE (415) 442-1304

Docket Number: 040853-01-5157-PR

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

Attorney Docket No.: 040853-01-5157-PR
Client Reference No.: NEO00320

PROVISIONAL

PATENT APPLICATION

GLYCOLIPIDS

Inventor(s): **Shawn DeFrees, a citizen of The United States, residing at
126 Filly Drive
North Wales, PA 19454**

**Zhi-Guang Wang, a citizen of The United States
and The Peoples Republic of China,
residing at
1473 Golden Drive
Dresher, PA 19025**

Assignee: **Neose Technologies, Inc.
102 Witmer Road
Horsham, PA 19044**

Entity: **Small**

**Todd Esker
Reg. No. 46,690**

**MORGAN
LEWIS AND
BOCKIUS
LLP**

Correspondence Address:

**One Market
Spear Street Tower
San Francisco
California 94105
Tel 415 442-1304
Fax 415 442-1000**

AS FILED IN THE USPTO ON Tuesday, November 09, 2004

GLYCOLIPIDS

BACKGROUND OF THE INVENTION

5 [0001] Gangliosides are glycosphingolipids, often found in cell membranes, that consist of three elements. One or more sialic acid residues are attached to an oligosaccharide or carbohydrate core moiety, which in turn is attached to a hydrophobic lipid (ceramide) structure which generally is embedded in the cell membrane. The ceramide moiety includes a long chain base (LCB) portion and a fatty acid (FA) portion. Gangliosides, as well as other glycolipids and their structures in general, are discussed in, for example, Lehninger (Biochemistry, Freeman, 4th Ed., 343-369 (2004)) and Devlin (Textbook of Biochemistry, Wiley-Liss, (1992)). Gangliosides are classified according to the number of monosaccharides in the carbohydrate moiety, as well as the number and location of sialic acid groups present

10 15 in the carbohydrate moiety. Mono sialogangliosides are given the designation "GM", disialogangliosides are designated "GD", trisialogangliosides "GT", and tetrasialogangliosides are designated "GQ". Gangliosides can be classified further depending on the position or positions of the sialic acid residue or residues bound. Further classification is based on the number of saccharides present in the

20 25 oligosaccharide core, with the subscript "1" designating a ganglioside that has four saccharide residues (Gal-GalNAc-Gal-Glc-Ceramide), and the subscripts "2", "3" and "4" representing trisaccharide (GalNAc-Gal-Glc-Ceramide), disaccharide (Gal-Glc-Ceramide) and monosaccharide (Gal-Ceramide) gangliosides, respectively.

[0002] Numerous types of gangliosides found in nature have been isolated and identified and vary primarily in the basic saccharide structure (e.g. GM3, GM2, GM1, GD1a, GD1b and GT1). A variety of procedures are available for the isolation and purification of such "natural" gangliosides from organs and tissues, particularly from animal brain (Sonnino *et al.*, *J. Lipid Res.*, 33:1221-1226 (1992); Sonnino *et al.*, *Ind. J. Biochem. Biophys.*, 25:144-14 (1988); Svennerholm, *Adv. Exp. Med. Biol.*, 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100 105 110 115 120 125 130 135 140 145 150 155 160 165 170 175 180 185 190 195 200 205 210 215 220 225 230 235 240 245 250 255 260 265 270 275 280 285 290 295 300 305 310 315 320 325 330 335 340 345 350 355 360 365 370 375 380 385 390 395 400 405 410 415 420 425 430 435 440 445 450 455 460 465 470 475 480 485 490 495 500 505 510 515 520 525 530 535 540 545 550 555 560 565 570 575 580 585 590 595 600 605 610 615 620 625 630 635 640 645 650 655 660 665 670 675 680 685 690 695 700 705 710 715 720 725 730 735 740 745 750 755 760 765 770 775 780 785 790 795 800 805 810 815 820 825 830 835 840 845 850 855 860 865 870 875 880 885 890 895 900 905 910 915 920 925 930 935 940 945 950 955 960 965 970 975 980 985 990 995 1000 1005 1010 1015 1020 1025 1030 1035 1040 1045 1050 1055 1060 1065 1070 1075 1080 1085 1090 1095 1100 1105 1110 1115 1120 1125 1130 1135 1140 1145 1150 1155 1160 1165 1170 1175 1180 1185 1190 1195 1200 1205 1210 1215 1220 1225 1230 1235 1240 1245 1250 1255 1260 1265 1270 1275 1280 1285 1290 1295 1300 1305 1310 1315 1320 1325 1330 1335 1340 1345 1350 1355 1360 1365 1370 1375 1380 1385 1390 1395 1400 1405 1410 1415 1420 1425 1430 1435 1440 1445 1450 1455 1460 1465 1470 1475 1480 1485 1490 1495 1500 1505 1510 1515 1520 1525 1530 1535 1540 1545 1550 1555 1560 1565 1570 1575 1580 1585 1590 1595 1600 1605 1610 1615 1620 1625 1630 1635 1640 1645 1650 1655 1660 1665 1670 1675 1680 1685 1690 1695 1700 1705 1710 1715 1720 1725 1730 1735 1740 1745 1750 1755 1760 1765 1770 1775 1780 1785 1790 1795 1800 1805 1810 1815 1820 1825 1830 1835 1840 1845 1850 1855 1860 1865 1870 1875 1880 1885 1890 1895 1900 1905 1910 1915 1920 1925 1930 1935 1940 1945 1950 1955 1960 1965 1970 1975 1980 1985 1990 1995 2000 2005 2010 2015 2020 2025 2030 2035 2040 2045 2050 2055 2060 2065 2070 2075 2080 2085 2090 2095 2100 2105 2110 2115 2120 2125 2130 2135 2140 2145 2150 2155 2160 2165 2170 2175 2180 2185 2190 2195 2200 2205 2210 2215 2220 2225 2230 2235 2240 2245 2250 2255 2260 2265 2270 2275 2280 2285 2290 2295 2300 2305 2310 2315 2320 2325 2330 2335 2340 2345 2350 2355 2360 2365 2370 2375 2380 2385 2390 2395 2400 2405 2410 2415 2420 2425 2430 2435 2440 2445 2450 2455 2460 2465 2470 2475 2480 2485 2490 2495 2500 2505 2510 2515 2520 2525 2530 2535 2540 2545 2550 2555 2560 2565 2570 2575 2580 2585 2590 2595 2600 2605 2610 2615 2620 2625 2630 2635 2640 2645 2650 2655 2660 2665 2670 2675 2680 2685 2690 2695 2700 2705 2710 2715 2720 2725 2730 2735 2740 2745 2750 2755 2760 2765 2770 2775 2780 2785 2790 2795 2800 2805 2810 2815 2820 2825 2830 2835 2840 2845 2850 2855 2860 2865 2870 2875 2880 2885 2890 2895 2900 2905 2910 2915 2920 2925 2930 2935 2940 2945 2950 2955 2960 2965 2970 2975 2980 2985 2990 2995 3000 3005 3010 3015 3020 3025 3030 3035 3040 3045 3050 3055 3060 3065 3070 3075 3080 3085 3090 3095 3100 3105 3110 3115 3120 3125 3130 3135 3140 3145 3150 3155 3160 3165 3170 3175 3180 3185 3190 3195 3200 3205 3210 3215 3220 3225 3230 3235 3240 3245 3250 3255 3260 3265 3270 3275 3280 3285 3290 3295 3300 3305 3310 3315 3320 3325 3330 3335 3340 3345 3350 3355 3360 3365 3370 3375 3380 3385 3390 3395 3400 3405 3410 3415 3420 3425 3430 3435 3440 3445 3450 3455 3460 3465 3470 3475 3480 3485 3490 3495 3500 3505 3510 3515 3520 3525 3530 3535 3540 3545 3550 3555 3560 3565 3570 3575 3580 3585 3590 3595 3600 3605 3610 3615 3620 3625 3630 3635 3640 3645 3650 3655 3660 3665 3670 3675 3680 3685 3690 3695 3700 3705 3710 3715 3720 3725 3730 3735 3740 3745 3750 3755 3760 3765 3770 3775 3780 3785 3790 3795 3800 3805 3810 3815 3820 3825 3830 3835 3840 3845 3850 3855 3860 3865 3870 3875 3880 3885 3890 3895 3900 3905 3910 3915 3920 3925 3930 3935 3940 3945 3950 3955 3960 3965 3970 3975 3980 3985 3990 3995 4000 4005 4010 4015 4020 4025 4030 4035 4040 4045 4050 4055 4060 4065 4070 4075 4080 4085 4090 4095 4100 4105 4110 4115 4120 4125 4130 4135 4140 4145 4150 4155 4160 4165 4170 4175 4180 4185 4190 4195 4200 4205 4210 4215 4220 4225 4230 4235 4240 4245 4250 4255 4260 4265 4270 4275 4280 4285 4290 4295 4300 4305 4310 4315 4320 4325 4330 4335 4340 4345 4350 4355 4360 4365 4370 4375 4380 4385 4390 4395 4400 4405 4410 4415 4420 4425 4430 4435 4440 4445 4450 4455 4460 4465 4470 4475 4480 4485 4490 4495 4500 4505 4510 4515 4520 4525 4530 4535 4540 4545 4550 4555 4560 4565 4570 4575 4580 4585 4590 4595 4600 4605 4610 4615 4620 4625 4630 4635 4640 4645 4650 4655 4660 4665 4670 4675 4680 4685 4690 4695 4700 4705 4710 4715 4720 4725 4730 4735 4740 4745 4750 4755 4760 4765 4770 4775 4780 4785 4790 4795 4800 4805 4810 4815 4820 4825 4830 4835 4840 4845 4850 4855 4860 4865 4870 4875 4880 4885 4890 4895 4900 4905 4910 4915 4920 4925 4930 4935 4940 4945 4950 4955 4960 4965 4970 4975 4980 4985 4990 4995 5000 5005 5010 5015 5020 5025 5030 5035 5040 5045 5050 5055 5060 5065 5070 5075 5080 5085 5090 5095 5100 5105 5110 5115 5120 5125 5130 5135 5140 5145 5150 5155 5160 5165 5170 5175 5180 5185 5190 5195 5200 5205 5210 5215 5220 5225 5230 5235 5240 5245 5250 5255 5260 5265 5270 5275 5280 5285 5290 5295 5300 5305 5310 5315 5320 5325 5330 5335 5340 5345 5350 5355 5360 5365 5370 5375 5380 5385 5390 5395 5400 5405 5410 5415 5420 5425 5430 5435 5440 5445 5450 5455 5460 5465 5470 5475 5480 5485 5490 5495 5500 5505 5510 5515 5520 5525 5530 5535 5540 5545 5550 5555 5560 5565 5570 5575 5580 5585 5590 5595 5600 5605 5610 5615 5620 5625 5630 5635 5640 5645 5650 5655 5660 5665 5670 5675 5680 5685 5690 5695 5700 5705 5710 5715 5720 5725 5730 5735 5740 5745 5750 5755 5760 5765 5770 5775 5780 5785 5790 5795 5800 5805 5810 5815 5820 5825 5830 5835 5840 5845 5850 5855 5860 5865 5870 5875 5880 5885 5890 5895 5900 5905 5910 5915 5920 5925 5930 5935 5940 5945 5950 5955 5960 5965 5970 5975 5980 5985 5990 5995 6000 6005 6010 6015 6020 6025 6030 6035 6040 6045 6050 6055 6060 6065 6070 6075 6080 6085 6090 6095 6100 6105 6110 6115 6120 6125 6130 6135 6140 6145 6150 6155 6160 6165 6170 6175 6180 6185 6190 6195 6200 6205 6210 6215 6220 6225 6230 6235 6240 6245 6250 6255 6260 6265 6270 6275 6280 6285 6290 6295 6300 6305 6310 6315 6320 6325 6330 6335 6340 6345 6350 6355 6360 6365 6370 6375 6380 6385 6390 6395 6400 6405 6410 6415 6420 6425 6430 6435 6440 6445 6450 6455 6460 6465 6470 6475 6480 6485 6490 6495 6500 6505 6510 6515 6520 6525 6530 6535 6540 6545 6550 6555 6560 6565 6570 6575 6580 6585 6590 6595 6600 6605 6610 6615 6620 6625 6630 6635 6640 6645 6650 6655 6660 6665 6670 6675 6680 6685 6690 6695 6700 6705 6710 6715 6720 6725 6730 6735 6740 6745 6750 6755 6760 6765 6770 6775 6780 6785 6790 6795 6800 6805 6810 6815 6820 6825 6830 6835 6840 6845 6850 6855 6860 6865 6870 6875 6880 6885 6890 6895 6900 6905 6910 6915 6920 6925 6930 6935 6940 6945 6950 6955 6960 6965 6970 6975 6980 6985 6990 6995 7000 7005 7010 7015 7020 7025 7030 7035 7040 7045 7050 7055 7060 7065 7070 7075 7080 7085 7090 7095 7100 7105 7110 7115 7120 7125 7130 7135 7140 7145 7150 7155 7160 7165 7170 7175 7180 7185 7190 7195 7200 7205 7210 7215 7220 7225 7230 7235 7240 7245 7250 7255 7260 7265 7270 7275 7280 7285 7290 7295 7300 7305 7310 7315 7320 7325 7330 7335 7340 7345 7350 7355 7360 7365 7370 7375 7380 7385 7390 7395 7400 7405 7410 7415 7420 7425 7430 7435 7440 7445 7450 7455 7460 7465 7470 7475 7480 7485 7490 7495 7500 7505 7510 7515 7520 7525 7530 7535 7540 7545 7550 7555 7560 7565 7570 7575 7580 7585 7590 7595 7600 7605 7610 7615 7620 7625 7630 7635 7640 7645 7650 7655 7660 7665 7670 7675 7680 7685 7690 7695 7700 7705 7710 7715 7720 7725 7730 7735 7740 7745 7750 7755 7760 7765 7770 7775 7780 7785 7790 7795 7800 7805 7810 7815 7820 7825 7830 7835 7840 7845 7850 7855 7860 7865 7870 7875 7880 7885 7890 7895 7900 7905 7910 7915 7920 7925 7930 7935 7940 7945 7950 7955 7960 7965 7970 7975 7980 7985 7990 7995 8000 8005 8010 8015 8020 8025 8030 8035 8040 8045 8050 8055 8060 8065 8070 8075 8080 8085 8090 8095 8100 8105 8110 8115 8120 8125 8130 8135 8140 8145 8150 8155 8160 8165 8170 8175 8180 8185 8190 8195 8200 8205 8210 8215 8220 8225 8230 8235 8240 8245 8250 8255 8260 8265 8270 8275 8280 8285 8290 8295 8300 8305 8310 8315 8320 8325 8330 8335 8340 8345 8350 8355 8360 8365 8370 8375 8380 8385 8390 8395 8400 8405 8410 8415 8420 8425 8430 8435 8440 8445 8450 8455 8460 8465 8470 8475 8480 8485 8490 8495 8500 8505 8510 8515 8520 8525 8530 8535 8540 8545 8550 8555 8560 8565 8570 8575 8580 8585 8590 8595 8600 8605 8610 8615 8620 8625 8630 8635 8640 8645 8650 8655 8660 8665 8670 8675 8680 8685 8690 8695 8700 8705 8710 8715 8720 8725 8730 8735 8740 8745 8750 8755 8760 8765 8770 8775 8780 8785 8790 8795 8800 8805 8810 8815 8820 8825 8830 8835 8840 8845 8850 8855 8860 8865 8870 8875 8880 8885 8890 8895 8900 8905 8910 8915 8920 8925 8930 8935 8940 8945 8950 8955 8960 8965 8970 8975 8980 8985 8990 8995 9000 9005 9010 9015 9020 9025 9030 9035 9040 9045 9050 9055 9060 9065 9070 9075 9080 9085 9090 9095 9100 9105 9110 9115 9120 9125 9130 9135 9140 9145 9150 9155 9160 9165 9170 9175 9180 9185 9190 9195 9200 9205 9210 9215 9220 9225 9230 9235 9240 9245 9250 9255 9260 9265 9270 9275 9280 9285 9290 9295 9300 9305 9310 9315 9320 9325 9330 9335 9340 9345 9350 9355 9360 9365 9370 9375 9380 9385 9390 9395 9400 9405 9410 9415 9420 9425 9430 9435 9440 9445 9450 9455 9460 9465 9470 9475 9480 9485 9490 9495 9500 9505 9510 9515 9520 9525 9530 9535 9540 9545 9550 9555 9560 9565 9570 9575 9580 9585 9590 9595 9600 9605 9610 9615 9620 9625 9630 9635 9640 9645 9650 9655 9660 9665 9670 9675 9680 9685 9690 9695 9700 9705 9710 9715 9720 9725 9730 9735 9740 9745 9750 9755 9760 9765 9770 9775 9780 9785 9790 9795 9800 9805 9810 9815 9820 9825 9830 9835 9840 9845 9850 9855 9860 9865 9870 9875 9880 9885 9890 9895 9900 9905 9910 9915 9920 9925 9930 9935 9940 9945 9950 9955 9960 9965 9970 9975 9980 9985 9990 9995 9999

[0003] Gangliosides are normal components of plasma membranes and are particularly abundant in the nervous system. In humans, gangliosides are most abundant in the gray matter of the brain, particularly in nerve endings. They are believed to be present at receptor sites for neurotransmitters, including acetylcholine, 5 and can also act as specific receptors for other biological macromolecules, including interferon, hormones, viruses, bacterial toxins, and the like.

[0004] Certain gangliosides are found on the surface of human hematopoietic cells (Hildebrand *et al.*, *Biochim. Biophys. Acta*, **260**: 272-278 (1972); Macher *et al.*, *J. Biol. Chem.* **256**:1968-1974 (1981); Dacremont *et al.*, *Biochim. Biophys. Acta* 10 **424**:315-322; Klock *et al.*, *Blood Cells* **7**:247 (1981)) which may play a role in the terminal granulocytic differentiation of these cells. Nojiri *et al.*, *J Biol. Chem.* **263**:7443-7446 (1988)). These gangliosides, referred to as the "neolacto" series, have neutral core oligosaccharide structures having the formula [Gal β -(1,4)GlcNAc β (1,3)]_nGal β (1,4)Glc, where n = 1-4. Included among these 15 neolacto series gangliosides are 3'-nLM₁ (NeuAc α (2,3)Gal β (1,4)GlcNAc β (1,3)Gal β (1,4)-Glc β (1,1)-Ceramide) and 6'-nLM₁ (NeuAc α (2,6)Gal β (1,4)GlcNAc β (1,3)Gal β (1,4)-Glc β (1,1)-Ceramide).

[0005] It has been widely demonstrated that gangliosides are able to enhance functional recovery both in the lesioned peripheral nervous system (PNS) and the 20 central nervous system (CNS), through the involvement of specific membrane mechanisms and the interaction with trophic factors, as pointed out from studies *in vitro* on neuronal cultures (Ferrari, F. *et al.*, *Dev. Brain Res.*, **8**:215-221 (1983); Doherty, P. *et al.*, *J. Neurochem.*, **44**:1259-1265 (1985); Skaper, S.D. *et al.*, *Mol. Neurobiol.*, **3**:173-199 (1989)). Gangliosides have been used for treatment of nervous 25 system disorders, including cerebral ischemic strokes. See, e.g., Mahadnik *et al.*, *Drug Development Res.*, **15**:337-360 (1988); US Patent Nos. 4,710,490 and 4,347,244; Horowitz, *Adv. Exp. Med. and Biol.*, **174**:593-600 (1988); Karpiatz *et al.*, *Adv. Exp. Med. and Biol.*, **174**:489-497 (1984).

[0006] As a result, attempts have been made to use gangliosides in the treatment 30 of disorders of the nervous system. This has led to the development of synthetic gangliosides as well as natural ganglioside containing compositions for use in the treatment of disorders of the nervous system (U.S. Pat. Nos. 4,476,119, 4,593,091,

4,639,437, 4,707,469, 4,713,374, 4,716,223, 4,849,413, 4,940,694, 5,045,532, 5,135,921, 5,183,807, 5,190,925, 5,210,185, 5,218,094, 5,229,373, 5,260,464, 5,264,424, 5,350,841, 5,424,294, 5,484,775, 5,519,007, 5,521,164, 5,523,294, 5,677,285, 5,792,858, 5,795,869, and 5,849,717).


5 [0007] Gangliosides have also been implicated as playing a significant role in certain types of cancer. Neuroblastoma is a form of cancer that primarily afflicts children under the age of five. Individuals suffering from neuroblastoma may have tumors growing near the spinal cord, and very large tumors have been found to cause paralysis in such patients. Gangliosides have been shown to play a role in both the 10 growth and the inhibition of the growth of neuroblastoma-associated tumors (Basavarajappa *et al.*, *Alcohol Clin. Exp. Res.*, 21(7):1199-1203 (1997); Singleton *et al.*, *Int. J. Dev. Neurosci.*, 18(8):797-780 (2000)).

15 [0008] However, there still exists a need in the art for compounds capable of acting as neuroprotective agents in a manner similar to or better than the natural gangliosides for the prophylaxis, treatment and cure of disorders of the nervous system. Further, differences in the structure of ganglioside compounds can refine the structure-function relationship of such compounds to provide powerful tools for control of the growth of certain kinds of tumors, including neuroblastoma tumors.


SUMMARY OF THE INVENTION

20 [0009] The present invention answers this need by providing novel synthetic gangliosides of formulae (I)-(III), which are listed below.

[0010] The invention further provides a novel synthetic ganglioside according to Formula (I):



25 in which X² can be




In the formulae above, R¹, R², R³, R⁴, and R⁵ can be independently selected from substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted arylalkyl, and substituted or unsubstituted heteroarylalkyl. Z² can be substituted or unsubstituted alkenyl, substituted or unsubstituted pyridinyl, and substituted or unsubstituted phenyl.


5

[0011] The present invention also provides a novel ganglioside as described above, with the proviso that when R¹ is -(CH₂)₁₆-CH₃, then Z² is not unsubstituted pyridinyl,

10




[0012] In another embodiment, X² can be




In the formula above, R¹ is substituted or unsubstituted alkyl. In yet another embodiment, R¹ can be a substituted or unsubstituted C₈-C₂₀ alkyl moiety. In still 15 another embodiment, wherein R¹ can be haloalkyl. In another embodiment, R¹ can be a member selected from chloromethyl and dichloromethyl.


[0013] The invention further provides a novel synthetic ganglioside according to Formula (II):



20 in which X³ can be




In the formulae above, R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ can be members independently selected from substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted arylalkyl, and substituted or unsubstituted heteroarylalkyl. J¹ can be -NR¹⁵R¹⁶, in which R¹⁵ and R¹⁶ can be members independently selected from substituted or unsubstituted alkyl. K¹ can be a member selected from substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl. In another embodiment, at least one member selected from R¹⁵ and R¹⁶ can be -(CH₂)₇-CH₃. In a further embodiment, K¹ can be substituted or unsubstituted aryl. In yet another embodiment, K¹ can be substituted or unsubstituted phenyl. In still another embodiment, X³ can be



In the formula above, R¹⁰ can be substituted or unsubstituted alkyl. In yet another embodiment, R¹⁰ can be a substituted or unsubstituted alkyl moiety. In another embodiment, R¹⁰ can be haloalkyl. In still another embodiment, R¹⁰ can be a member selected from chloromethyl and dichloromethyl.

[0014] The invention further provides a novel synthetic ganglioside according to Formula (III):




In the formula above, X⁴ can be substituted or unsubstituted alkyl, -C(=M²)R²⁰, -C(=M²)-Q²-R²⁰, -SO₂R²⁰. R²⁰ can be a member selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl. M² and Q² can be independently selected from O, NR²¹ and S. R²¹ can be H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted

heterocycloalkyl. A^1 and A^2 can be independently selected from H, substituted or unsubstituted alkyl, and substituted or unsubstituted heteroalkyl. K^2 can be substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted arylalkyl, and substituted or unsubstituted heteroarylalkyl.

5


[0015] The present also provides a novel ganglioside compound as described above, with the proviso that if A^1 is $-(CH_2)_7-CH_3$, A^2 is $-(CH_2)_7-CH_3$, X^4 is $-C(=O)R^{20}$, and R^{20} is $-(CH_2)_{16}-CH_3$, then K^2 is not unsubstituted phenyl.

[0016] In another embodiment of the invention, X^4 can be $-C(=O)R^{20}$, and R^{20} can 10 be substituted or unsubstituted alkyl. In yet another embodiment of the invention, X^4 can be



In yet another embodiment, A^1 and A^2 can be independently selected from substituted or unsubstituted alkyl. In still another embodiment, A^1 and A^2 can be $-(CH_2)_7-CH_3$. 15 In another embodiment, K^2 can be substituted or unsubstituted aryl. In still another embodiment, K^2 can be phenyl.

[0017] The present invention also provides a novel ganglioside compound in which the saccharide component can be



20

and such saccharide moieties may or may not be deacetylated.


[0018] The invention further provides pharmaceutical compositions including at least one compound of the invention and a pharmaceutically acceptable carrier.

[0019] The invention still further provides a method for the prevention and/or 25 treatment and/or cure of a disorder of the nervous system in an animal or human including the step of administering to a patient in need thereof a therapeutically

effective amount of at least one compound or pharmaceutical composition of the invention. Such patients in need of a compound of the present invention may suffer from a disorder of the nervous system, including Parkinson's disease, ischemia, stroke, Alzheimer's disease, depression, anxiety, encephalitis, meningitis, 5 amyotrophic lateral sclerosis, trauma, spinal cord injury, nerve injury, and nerve regeneration.

[0020] One embodiment of the invention provides a method for the treatment of a glioma in a human and includes the step of administering to the human in need thereof a therapeutically effective amount of a compound of the present invention.


10 [0021] The present invention also provides a method of synthesizing a synthetic ganglioside compound of the invention, wherein the steps of synthesis of the saccharide moiety include contacting a sphingoid acceptor molecule and a glucose molecule with a galactosyltransferase enzyme and a galactose donor molecule to form




15 contacting the



with a trans-sialidase enzyme and a sialic acid (NANA) donor molecule to form




contacting the




20

with a N-acetyl galactose (GalNAc)-transferase enzyme and a GalNAc donor molecule to form




contacting the



with a galactosyltransferase enzyme and a galactose (Gal) donor molecule to form



, and
contacting the



5

with a fatty acid moiety under conditions sufficient to form a ganglioside.

DETAILED DESCRIPTION OF THE INVENTION

A. Introduction

[0022] Novel synthetic ganglioside compositions are described herein. Following 10 a discussion of the ganglioside compositions, methods of making the synthetic ganglioside compositions, pharmaceutical compositions containing such synthetic gangliosides, and methods of using the synthetic ganglioside compositions as neuroprotecting agents are also presented.

B. Definitions

15 [0023] In accordance with the invention and as used herein, the following terms are defined with the following meanings, unless explicitly stated otherwise.

[0024] The article "a" and "an" as used herein refers to one or to more than one (i.e. at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.

20 [0025] The term "alkenyl" as used herein refers to a substituted or unsubstituted trivalent straight chain or branched chain unsaturated aliphatic radical that includes at least two carbons joined by a double bond.

[0026] The term "alkynyl" as used herein refers to a straight or branched chain aliphatic radical that includes at least two carbons joined by a triple bond. If no

number of carbons is specified, "alkenyl" and "alkynyl" each refer to radicals having from 2-12 carbon atoms.

[0027] The term "cycloalkyl" as used herein refers to a substituted or unsubstituted saturated aliphatic ring system, preferably a mono-, bi-, or tricyclic saturated aliphatic ring system. Examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl, cyclooctyl, [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane (decalin), and [2.2.2]bicyclooctane.

[0028] The term "aromatic" is intended to mean stable substituted or unsubstituted mono-, bi-, tri-, polycyclic ring structures having only carbon atoms as ring atoms including, but not limited to, a stable monocyclic ring which is aromatic having six ring atoms; a stable bicyclic ring structure having a total of from 7 to 12 carbon atoms in the two rings of which at least one of the rings is aromatic; and a stable tricyclic ring structure having a total of from 10 to 16 atoms in the three rings wherein the tricyclic ring structure of which at least one of the ring is aromatic. Any non-aromatic rings present in the monocyclic, bicyclic, tricyclic or polycyclic ring structure may independently be saturated, partially saturated or fully saturated. Examples of such "aromatic" groups include, but are not limited to, phenyl and naphthyl.

[0029] The term "arylalkyl" as used herein refers to one, two, or three substituted or unsubstituted aryl groups having the number of carbon atoms designated appended to an alkyl group having the number of carbon atoms designated. The direction of attachment of an arylalkyl group to the remainder of the molecule may be through either the aryl or alkyl portion of the group. Suitable arylalkyl groups include, but are not limited to, benzyl, picolyl, naphthylmethyl, phenethyl, benzylhydryl, trityl, and the like, all of which may be optionally substituted.

[0030] As used herein the term "heteroaryl," "heteroaromatic" or "aromatic heterocyclic ring system" refers to a monocyclic, bicyclic or polycyclic, substituted or unsubstituted heterocyclic ring system containing at least one aromatic ring.

[0031] The term "substituted" as used herein means that a hydrogen atom has been replaced with another monovalent group (e.g. halo, haloalkyl, hydroxy, thiol, alkoxy, thiohaloalkyl, amino, and the like).

[0032] The terms "halo" or "halogen" as used herein refer to Cl, Br, F or I. The term "haloalkyl" and the like, refer to an alkyl group, as defined herein, wherein at least one hydrogen atom of the alkyl group is replaced by a Cl, Br, F or I. A mixture of different halo atoms may be used if more than one hydrogen atom is replaced. For 5 example, a haloalkyl includes chloromethyl (-CH₂Cl) and trifluoromethyl (-CF₃) and the like.

[0033] The term "methylene" refers to -CH₂-.

[0034] Where substituent groups are specified by their conventional chemical formulae, written from left to right, they equally encompass the chemically identical 10 substituents which would result from writing the structure from right to left, *e.g.*, -CH₂O- is intended to also recite -OCH₂-.

[0035] The term "alkyl," by itself or as part of another substituent, means, unless otherwise stated, a straight or branched chain, or cyclic hydrocarbon radical, or combination thereof, which may be fully saturated, mono- or polyunsaturated and can 15 include di- and multivalent radicals, having the number of carbon atoms designated (*i.e.* C₁-C₁₀ means one to ten carbons). Examples of saturated hydrocarbon radicals include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, cyclohexyl, (cyclohexyl)methyl, cyclopropylmethyl, homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. An unsaturated alkyl group is one having one or more 20 double bonds or triple bonds. Examples of unsaturated alkyl groups include, but are not limited to, vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and the higher homologs and isomers. The term "alkyl," unless otherwise noted, is also 25 meant to include those derivatives of alkyl defined in more detail below, such as "heteroalkyl." Alkyl groups which are limited to hydrocarbon groups are termed "homoalkyl".

[0036] The term "alkylene" by itself or as part of another substituent means a 30 divalent radical derived from an alkane, as exemplified, but not limited, by -CH₂CH₂CH₂CH₂-, and further includes those groups described below as "heteroalkylene." Typically, an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being preferred in

the present invention. A "lower alkyl" or "lower alkylene" is a shorter chain alkyl or alkylene group, generally having eight or fewer carbon atoms.

[0037] The terms "alkoxy," "alkylamino" and "alkylthio" (or thioalkoxy) are used in their conventional sense, and refer to those alkyl groups attached to the remainder of the molecule via an oxygen atom, an amino group, or a sulfur atom, respectively.

[0038] The term "heteroalkyl," by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or cyclic hydrocarbon radical, or combinations thereof, consisting of the stated number of carbon atoms and at least one heteroatom selected from the group consisting of O, N, 10 Si and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized. The heteroatom(s) O, N and S and Si may be placed at any interior position of the heteroalkyl group or at the position at which the alkyl group is attached to the remainder of the molecule. Examples include, but are not limited to, -CH₂-CH₂-O-CH₃, -CH₂-CH₂-NH-CH₃, -CH₂-CH₂-N(CH₃)-CH₃, -CH₂-S-CH₂-CH₃, -CH₂-CH₂-S(O)-CH₃, -CH₂-CH₂-S(O)₂-CH₃, -CH=CH-O-CH₃, -Si(CH₃)₃, -CH₂-CH=N-OCH₃, and -CH=CH-N(CH₃)-CH₃. 15 Up to two heteroatoms may be consecutive, such as, for example, -CH₂-NH-OCH₃ and -CH₂-O-Si(CH₃)₃. Similarly, the term "heteroalkylene" by itself or as part of another substituent means a divalent radical derived from heteroalkyl, as exemplified, 20 but not limited by, -CH₂-CH₂-S-CH₂-CH₂- and -CH₂-S-CH₂-CH₂-NH-CH₂- For heteroalkylene groups, heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, and the like). Still further, for alkylene and heteroalkylene linking groups, no orientation of 25 the linking group is implied by the direction in which the formula of the linking group is written. For example, the formula -C(O)₂R'- represents both -C(O)₂R'- and -R'C(O)₂-.

[0039] The terms "cycloalkyl" and "heterocycloalkyl", by themselves or in combination with other terms, represent, unless otherwise stated, cyclic versions of "alkyl" and "heteroalkyl", respectively. Additionally, for heterocycloalkyl, a 30 heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule. Examples of cycloalkyl include, but are not limited to, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like.

Examples of heterocycloalkyl include, but are not limited to, 1-(1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl, and the like.

5 [0040] Examples of "heterocycles", "heterocyclic rings" or "heterocyclic ring systems" include, but are not limited to, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazaliny, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, 10 decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl (benzimidazolyl), isothiazolyl, isoxazolyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 15 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, 20 pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 6H-1,2,5-thiadazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, 25 thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl and xanthenyl. Also included are fused ring and spiro compounds containing, for example, the above heterocyclic ring structures.

[0041] The terms "halo" or "halogen," by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom. Additionally, terms such as "haloalkyl," are meant to include monohaloalkyl and polyhaloalkyl. For example, the term "halo(C₁-C₄)alkyl" is mean to include, but not be limited to, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.

[0042] The term "aryl" means, unless otherwise stated, a polyunsaturated, aromatic, hydrocarbon substituent which can be a single ring or multiple rings (preferably from 1 to 3 rings) which are fused together or linked covalently. The term "heteroaryl" refers to aryl groups (or rings) that contain from one to four heteroatoms selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized. A heteroaryl group can be attached to the remainder of the molecule through a heteroatom. Non-limiting examples of aryl and heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, 10 pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinolyl, 5-isoquinolyl, 2-quinoxaliny, 5-quinoxaliny, 3-quinolyl, and 6-quinolyl. Substituents for each of the 15 above noted aryl and heteroaryl ring systems are selected from the group of acceptable substituents described below.

[0043] For brevity, the term "aryl" when used in combination with other terms (e.g., aryloxy, arylthioxy, arylalkyl) includes both aryl and heteroaryl rings as defined above. Thus, the term "arylalkyl" is meant to include those radicals in which an aryl group is attached to an alkyl group (e.g., benzyl, phenethyl, pyridylmethyl and the like) including those alkyl groups in which a carbon atom (e.g., a methylene group) has been replaced by, for example, an oxygen atom (e.g., phenoxyethyl, 2-pyridyloxymethyl, 3-(1-naphthoxy)propyl, and the like).

[0044] Each of the above terms (e.g., "alkyl," "heteroalkyl," "aryl" and "heteroaryl") are meant to include both substituted and unsubstituted forms of the indicated radical. Preferred substituents for each type of radical are provided below.

[0045] Substituents for the alkyl and heteroalkyl radicals (including those groups often referred to as alkylene, alkenyl, heteroalkylene, heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl) can be one or 30 more of a variety of groups selected from, but not limited to: -OR', =O, =NR', =N-OR', -NR'R", -SR', -halogen, -SiR'R'R", -OC(O)R', -C(O)R', -CO₂R', -CONR'R", -OC(O)NR'R", -NR"C(O)R', -NR'-C(O)NR'R", -NR"C(O)₂R', -NR-

C(NR'R'R'')=NR''', -NR-C(NR'R')=NR''', -S(O)R', -S(O)₂R', -S(O)₂NR'R'', -NRSO₂R', -CN and -NO₂ in a number ranging from zero to (2m'+1), where m' is the total number of carbon atoms in such radical. R', R'', R''' and R'''' each preferably independently refer to hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, *e.g.*, aryl substituted with 1-3 halogens, substituted or unsubstituted alkyl, alkoxy or thioalkoxy groups, or arylalkyl groups. When a compound of the invention includes more than one R group, for example, each of the R groups is independently selected as are each R', R'', R''' and R'''' groups when more than one of these groups is present. When R' and R'' are attached to the same 10 nitrogen atom, they can be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring. For example, -NR'R'' is meant to include, but not be limited to, 1-pyrrolidinyl and 4-morpholinyl. From the above discussion of substituents, one of skill in the art will understand that the term "alkyl" is meant to include groups including carbon atoms bound to groups other than hydrogen groups, such as 15 haloalkyl (*e.g.*, -CF₃ and -CH₂CF₃) and acyl (*e.g.*, -C(O)CH₃, -C(O)CF₃, -C(O)CH₂OCH₃, and the like).

[0046] Similar to the substituents described for the alkyl radical, substituents for the aryl and heteroaryl groups are varied and are selected from, for example: halogen, -OR', =O, =NR', =N-OR', -NR'R'', -SR', -halogen, -SiR'R'R''', -OC(O)R', -C(O)R', -CO₂R', -CONR'R'', -OC(O)NR'R'', -NR''C(O)R', -NR'-C(O)NR''R'', -NR''C(O)R', -NR-C(NR'R'R'')=NR''', -NR-C(NR'R')=NR''', -S(O)R', -S(O)₂R', -S(O)₂NR'R'', -NRSO₂R', -CN and -NO₂, -R', -N₃, -CH(Ph)₂, fluoro(C₁-C₄)alkoxy, and fluoro(C₁-C₄)alkyl, in a number ranging from zero to the total number of open valences on the aromatic ring system; and where R', R'', R''' and R'''' are preferably 20 independently selected from hydrogen, (C₁-C₈)alkyl and heteroalkyl, unsubstituted aryl and heteroaryl, (unsubstituted aryl)-(C₁-C₄)alkyl, and (unsubstituted aryl)oxy-(C₁-C₄)alkyl. When a compound of the invention includes more than one R group, for example, each of the R groups is independently selected as are each R', R'', R''' and R'''' groups when more than one of these groups is present.

30 [0047] Two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -T-C(O)-(CRR')_q-U-, wherein T and U are independently -NR-, -O-, -CRR'- or a single bond, and q is an integer of from 0 to 3. Alternatively, two of the substituents on adjacent atoms of the

aryl or heteroaryl ring may optionally be replaced with a substituent of the formula –A-(CH₂)_r-B-, wherein A and B are independently –CRR'-, -O-, -NR-, -S-, -S(O)-, -S(O)₂-, -S(O)₂NR'- or a single bond, and r is an integer of from 1 to 4. One of the single bonds of the new ring so formed may optionally be replaced with a double bond. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula –(CRR')_s-X-(CR"R"')_d-, where s and d are independently integers of from 0 to 3, and X is –O-, -NR'-, -S-, -S(O)-, -S(O)₂-, or -S(O)₂NR'-.

10 The substituents R, R', R" and R"'' are preferably independently selected from hydrogen or substituted or unsubstituted (C₁-C₆)alkyl.

[0048] As used herein, the term "heteroatom" is meant to include oxygen (O), nitrogen (N), sulfur (S) and silicon (Si).

[0049] The term "pharmaceutically acceptable salts" is meant to include salts of the active compounds which are prepared with relatively nontoxic acids or bases, 15 depending on the particular substituents found on the compounds described herein. When compounds of the present invention contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable base addition salts include sodium, 20 potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt. When compounds of the present invention contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived 25 from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, 30 lactic, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge *et al.*, "Pharmaceutical Salts", *Journal of*

Pharmaceutical Science, 66:1-19 (1977)). Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.

[0050] The neutral forms of the compounds are preferably regenerated by 5 contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents.

[0051] In addition to salt forms, the present invention provides compounds, which 10 are in a prodrug form. Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the present invention. Additionally, prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an *ex vivo* environment. For example, prodrugs can be slowly converted 15 to the compounds of the present invention when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.

[0052] Certain compounds of the present invention can exist in unsolvated forms 20 as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are encompassed within the scope of the present invention. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the 25 uses contemplated by the present invention and are intended to be within the scope of the present invention.

[0053] Certain compounds of the present invention possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometric 25 isomers and individual isomers are encompassed within the scope of the present invention.

[0054] The compounds of the present invention may also contain unnatural 30 proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the compounds may be radiolabeled with radioactive isotopes, such as for example tritium (^3H), iodine-125 (^{125}I) or carbon-14 (^{14}C). All isotopic variations of the compounds of the present invention, whether radioactive or not, are intended to be encompassed within the scope of the present invention.

[0055] "Pharmaceutically acceptable acid addition salt" as used herein refers to salts retaining the biological effectiveness and properties of the free bases and which are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicyclic acid and the like.

[0056] "Pharmaceutically acceptable base addition salts" as used herein refers to those salts derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Salts derived from pharmaceutically acceptable organic nontoxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-diethylaminoethanol, trimethamine, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins and the like.

[0057] The term "biological property" as used herein means an *in vivo* activity that is directly or indirectly performed by a compound or pharmaceutical composition of the invention that is often shown by *in vitro* assays. In the present invention, the biological property is neuroprotection, including the prophylaxis, treatment and/or cure of disorders of the nervous system.

[0058] The term "isomer" as used herein refers to a compound having the same number and kind of atoms and hence the same molecular weight as another compound, but differing in respect to the arrangement or configuration of the atoms of the compound (e.g. *cis* and *trans* isomers). The term "isomer" also includes stereoisomers, diastereoisomers, enantiomers or mixtures thereof. The D-isomer is preferred.

[0059] The term "substructure" as used herein refers to a portion of a chemical compound. For example, a single aromatic ring of a naphthalene structure is herein referred to as a substructure of the entire naphthalene molecule.

[0060] The term "hydrate" as used herein refers to the product of water with a compound of the invention such that the H-OH bond is not split. A compound of the invention may form more than one hydrate. However, the amount of water in a hydrate of the invention is such that the compound remains stable. Preferably, a hydrate of a compound of the invention contains about 0.1-10% water.

[0061] The term "prodrug" as used herein refers to a pharmacologically inactive derivative or precursor of a compound of the invention which upon biotransformation, either spontaneous or enzymatic, within an organism releases a compound of the invention as a pharmaceutically active drug. A prodrug derivative of a compound of the invention contain groups cleavable under metabolic conditions such as, for example, solvolysis under physiological conditions or enzymatic degradation.

According to the invention, a compound of the invention resulting from the biotransformation of its prodrug derivative are pharmaceutically active in vivo. Prodrug derivatives of a compound of the invention may be designated as single, double, triple, etc., corresponding to the number of biotransformation steps required to release the pharmaceutically active compound of the invention within the organism and/or indicating the number of functionalities present in the prodrug derivative. Prodrugs often offer advantages of solubility, tissue compatibility, or delayed release in the mammalian organism (see, Bundgard, Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam (1985) and Silverman, The Organic Chemistry of Drug Design and Drug Action, pp. 352-401, Academic Press, San Diego, CA, (1992)).

[0062] As used herein, the term "saccharide" may be used interchangeably with the term "carbohydrate" and refers to single simple sugar moieties or monosaccharides as well as combinations of two or more single sugar moieties or monosaccharides covalently linked to form disaccharides, oligosaccharides, and polysaccharides. The term "saccharide" also includes N-acetylated and N-deacylated derivatives of such monosaccharides, disaccharides, oligosaccharides, and polysaccharides. Saccharides for use in the invention may be linear or branched. Examples of suitable monosaccharides include, but are not limited to, known aldoses

and ketoses (*i.e.* aldehyde and ketone derivatives of straight-chain polyhydroxy alcohols containing at least three carbon atoms) including, for example, glyceraldehyde, erythrose, threose, ribose (Rib), arabinose (Ara), xylose (Xyl), lyxose (Lyx), allose, altrose, glucose (Glc), mannose (Man), gulose, idose, galactose (Gal), 5 talose, dihydroxyacetone, erythrulose, ribulose, xylulose, psicose, fructose (Frc), sorbose, and tagatose. Other examples of suitable monosaccharides include, but are not limited to, fucose (Fuc), N-acetylneurameric acid (also called sialic acid, NANA, or NAN (Sia)), N-acetylglucosamine (GlcNAc), and N-acetylgalactosamine (GalNAc). The cyclic hemiacetal and hemiketal forms of the monosaccharides are 10 contemplated within the defined term. Other examples of suitable saccharides include, but are not limited to, those illustrated in Figure 1.

[0063] As used herein, the term "disaccharide" refers to a saccharide composed of two monosaccharides linked together by a glycosidic bond. Examples of disaccharides include, but are not limited to, lactose (Lac) (glycosidic bond between 15 Gal and Glc), sucrose (Suc) (glycosidic bond between Frc and Glc), and maltose (Mal), isomaltose and cellobiose (glycosidic bond between Glc and Glc).

[0064] The term "oligosaccharide" includes an oligosaccharide that has a reducing end and a non-reducing end, whether or not the saccharide at the reducing end is in fact a reducing sugar. In accordance with accepted nomenclature, an 20 oligosaccharide is depicted herein with the non-reducing end on the left and the reducing end on the right. An oligosaccharide described herein may be described with the name or abbreviation for the non-reducing saccharide (*e.g.*, Gal), followed by the configuration of the glycosidic bond (α or β), the ring bond, the ring position of the reducing saccharide involved in the bond, and then the name or abbreviation of 25 the reducing saccharide (*e.g.*, GlcNAc). The linkage between two sugars may be expressed, for example, as 2,3,2-->3, 2-3, or (2,3).

[0065] The term "sphingoid," as used herein, includes sphingosines, phytosphingosines, sphinganines, ceramides, and the like. Both naturally occurring and synthetically produced compounds are included.

30 [0066] The term "glycosphingolipid" is a carbohydrate-containing derivative of a sphingoid or ceramide. The carbohydrate residue is attached by a glycosidic linkage to O-1 of the sphingoid.

[0067] The term "sialic acid" (abbreviated "Sia") refers to any member of a family of nine-carbon carboxylated sugars. The most common member of the sialic acid family is N-acetyl-neuraminic acid (2-keto-5-acetamido-3,5-dideoxy-D-glycero-D-galactononulopyranos-1-onic acid (often abbreviated as Neu5Ac, NeuAc, or NANA). A second member of the family is N-glycolyl-neuraminic acid (Neu5Gc or NeuGc), in which the N-acetyl group of NeuAc is hydroxylated. A third sialic acid family member is 2-keto-3-deoxy-nonulosonic acid (KDN) (Nadano et al. (1986) *J. Biol. Chem.* 261: 11550-11557; Kanamori et al. (1990) *J. Biol. Chem.* 265: 21811-21819. Also included are 9-substituted sialic acids such as a 9-O-C₁-C₆ acyl-Neu5Ac like 9-O-lactyl-Neu5Ac or 9-O-acetylNeu5Ac, 9-deoxy-9-fluoro-Neu5Ac and 9-azido-9-deoxy-Neu5Ac. For review of the sialic acid family, see, e.g., Varki (1992) *Glycobiology* 2:25-40; *Sialic Acids: Chemistry, Metabolism and Function*, R. Schauer, Ed. (Springer-Verlag, New York (1992). The synthesis and use of sialic acid compounds in a sialylation procedure is described in, for example, international application WO 92/16640, published October 1, 1992.

[0068] As used herein, the term "linker" refers to any element, atom, molecule, that serves to join one portion of a molecule to another. Linkers are well known to those skilled in the art. Linkers can be mono- or multifunctional.

[0069] As used herein, the term "donor" refers to any molecule that serves to 20 donate or provide a monosaccharide for addition to a growing saccharide chain or acceptor molecule. Thus the sugar moiety serves as one part of a donor molecule. Generally, the monosaccharide moiety is transferred from the donor to an "acceptor," as defined herein, by means of an enzymatic reaction. Donor molecules include those known to those of skill in the art and will vary depending upon the desired 25 monosaccharide to be transferred.

[0070] As used herein, the term "contacting" or "contact" in relation to an enzyme and "donor" and an "acceptor" to form a growing saccharide chain means bringing the enzyme and donor into association with the "acceptor" or growing saccharide chain to affect the addition of a new monosaccharide unit to the acceptor or growing 30 saccharide chain.

[0071] As used herein, the term "acceptor" refers to a molecule capable of receiving a monosaccharide moiety from a donor, each as defined herein. An

“acceptor” may accept more than one monosaccharide such that a linear or branched “saccharide,” as defined above, can be formed. Thus, the term “acceptor” includes a molecule containing a growing saccharide chain.

5 [0072] As used herein, the term “non-immobilized” in reference to an “acceptor”, as defined herein, means that the acceptor is not affixed or bound to a substrate. For example, an acceptor that is in solution would be a “non-immobilized” acceptor.

10 [0073] The term “glycosyltransferase” as used herein refers to enzymes that catalyze the transfer of sugar moieties from activated donor molecules to specific acceptor molecules, each as defined herein, forming glycosidic bonds. Examples of glycosyltransferases include, but are not limited to, galactosyltransferase, glucosyltransferase, fucosyltransferase, and GalNActransferase. Further, glycosyltransferases may be classified according to the stereochemistries of the reaction substrates and products as either retaining, *i.e.*, leading to retention of the anomeric configuration (for instance UDP-glucose \rightarrow α -glucoside), or inverting, *i.e.*,

15 leading to inversion of the anomeric configuration (for instance UDP-glucose \rightarrow β -glucoside) (Sinnott, M.L. *Chem. Rev.*, 90:1171-1202 (1990)). The classification groupings of families of glycosyltransferases is explained by Coutinho, P.M. & Henrissat, B. (1999) Carbohydrate-Active Enzymes server, which can be found on the Internet at <<afmb.cnrs-mrs.fr/~pedro/CAZY/db.html>>.


20 [0074] As used herein, the term “trans-sialidase” refers to an enzyme that catalyzes the addition of a sialic acid to galactose by means of an α -2,3 glycosidic linkage. Trans-sialidases may be found in many *Trypanosomyces* species and some other parasites. Trans-sialidases of these parasite organisms retain the hydrolytic activity of usual sialidase, but with much less efficiency, and catalyze a reversible transfer of terminal sialic acids from host sialoglycoconjugates to parasite surface glycoproteins in the absence of CMP-sialic acid. *Trypanosome cruzi*, which causes Chagas disease, has a surface trans-sialidase that catalyzes preferentially the transference of α -2,3-linked sialic acid to acceptors containing terminal β -galactosyl residues, instead of the typical hydrolysis reaction of most sialidases (Ribeirão *et al.*, 25 *Glycobiol.*, 7:1237-1246 (1997); Takahashi *et al.*, *Anal. Biochem.*, 230:333-342 (1995); Scudder *et al.*, *J. Biol. Chem.*, 268:9886-9891 (1993); Vandekerckhove *et al.*, *Glycobiol.*, 2:541-548 (1992)). *T. cruzi* trans-sialidase (TcTs) has activity towards a

wide range of saccharide, glycolipid, and glycoprotein acceptors which terminate with a β -linked galactose residue, and synthesizes exclusively an α 2-3 sialosidic linkage (Scudder et al., *supra*). At a low rate, it also transfers sialic acid from synthetic α -sialosides, such as p-nitrophenyl- α -N-acetylneuraminic acid, but NeuAc2-3Gal β 1-4(Fuc α 1-3)Glc is not a donor-substrate. Modified 2-[4-methylumbellifero]e- α -ketoside of N-acetyl-D-neuraminic acid (4MU-NANA) and several derivatives thereof can also serve as donors for TcTs (Lee & Lee, *Anal. Biochem.*, 216:358-364 (1994)). Enzymatic synthesis of 3'-sialyl-lacto-N-biose I has been catalyzed by TcTs from lacto-N-biose I as acceptor and 2'-(4-methylumbelliferyl)- α -D-N-
 10 acetylneuraminic acid donor of the N-acetylneuraminil moiety (Vetere et al., *Eur. J. Biochem.*, 267:942-949 (2000)). Further information regarding the use of trans-sialidase to synthesize α 2,3-sialylated conjugates can be found in European Patent Application No. 0 557 580 A2 and U.S. Patent No. 5,409,817. The intramolecular trans-sialidase from the leech *Macrobdella decora* exhibits strict specificity toward the
 15 cleavage of terminal Neu5Ac (N-acetylneuraminic acid) α 2 \rightarrow 3Gal linkage in sialoglycoconjugates and catalyzes an intramolecular trans-sialosyl reaction (Luo et al., *J. Mol. Biol.*, 285:323-332 (1999)). Trans-sialidases primarily add sialic acid onto galactose acceptors, but will transfer sialic acid onto some other sugars. Transfer of sialic acid onto GalNAc, however, requires a sialyltransferase. Further information
 20 on the use of trans-sialidases can be found in PCT Application No. WO 93/18787; Vetere et al., *Eur. J. Biochem.*, 247:1083-1090 (1997).


[0075] As used herein, the term "sialyltransferase" refers to enzymes that catalyze glycoside synthesis by inversion of the configuration of the added sugar and which require sugar nucleotides as the monosaccharide donor. An example of a
 25 sialyltransferase is the enzyme from the trypanosome *Trypanosoma rangeli* called TrSA (Buschiazzo et al., *EMBO J.*, 19:16-24 (2000)).

C. The Compositions

[0076] The invention provides a novel synthetic ganglioside according to formula (I):




in which X^2 can be




In the formulae above, R^1 , R^2 , R^3 , R^4 , and R^5 can be independently selected from substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted arylalkyl, and substituted or unsubstituted heteroarylalkyl. Z^2 can be substituted or unsubstituted alkenyl, substituted or unsubstituted pyridinyl, and substituted or unsubstituted phenyl.

[0077] The present invention also provides a novel ganglioside as described above, with the proviso that when R^1 is $-(CH_2)_{16}-CH_3$, then Z^2 is not unsubstituted pyridinyl,




[0078] In another embodiment, X^2 can be




In the formula above, R^1 is substituted or unsubstituted alkyl. In yet another embodiment, R^1 can be a substituted or unsubstituted C_8-C_{20} alkyl moiety. In still another embodiment, wherein R^1 can be haloalkyl. In another embodiment, R^1 can be a member selected from chloromethyl and dichloromethyl.

[0079] The invention further provides a novel synthetic ganglioside according to Formula (II):




20

in which X^3 can be




In the formulae above, R^{10} , R^{11} , R^{12} , R^{13} , and R^{14} can be members independently selected from substituted or unsubstituted alkyl, substituted or unsubstituted aryl, 5 substituted or unsubstituted heteroaryl, substituted or unsubstituted arylalkyl, and substituted or unsubstituted heteroarylalkyl. J^1 can be $-NR^{15}R^{16}$, in which R^{15} and R^{16} can be members independently selected from substituted or unsubstituted alkyl. K^1 can be a member selected from substituted or unsubstituted aryl and substituted or 10 unsubstituted heteroaryl. In another embodiment, at least one member selected from R^{15} and R^{16} can be $-(CH_2)_7-CH_3$. In a further embodiment, K^1 can be substituted or unsubstituted aryl. In yet another embodiment, K^1 can be substituted or unsubstituted phenyl. In still another embodiment, X^3 can be



In the formula above, R^{10} can be substituted or unsubstituted alkyl. In yet another 15 embodiment, R^{10} can be a substituted or unsubstituted alkyl moiety. In another embodiment, R^{10} can be haloalkyl. In still another embodiment, R^{10} can be a member selected from chloromethyl and dichloromethyl.

[0080] The invention further provides a novel synthetic ganglioside according to Formula (III):




20

in which X^4 can be substituted or unsubstituted alkyl, $-C(=M^2)R^{20}$, $-C(=M^2)-Q^2-R^{20}$, $-SO_2R^{20}$. R^{20} can be a member selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl. M^2 and Q^2 can be independently selected from O, NR^{21} and S. R^{21} can be H, substituted or unsubstituted alkyl, substituted or

unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl. A¹ and A² can be independently selected from H, substituted or unsubstituted alkyl, and substituted or unsubstituted heteroalkyl. K² can be substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted arylalkyl, and substituted or unsubstituted heteroarylalkyl.


[0081] The present also provides a novel ganglioside compound as described above, with the proviso that if A^1 is $-(CH_2)_7-CH_3$, A^2 is $-(CH_2)_7-CH_3$, X^4 is $-C(=O)R^{20}$, and R^{20} is $-(CH_2)_{16}-CH_3$, then K^2 is not unsubstituted phenyl.

10 [0082] In another embodiment of the invention, X^4 can be $-C(=O)R^{20}$, and R^{20} can be substituted or unsubstituted alkyl. In yet another embodiment of the invention, X^4 can be




15 In yet another embodiment, A^1 and A^2 can be independently selected from substituted or unsubstituted alkyl. In still another embodiment, A^1 and A^2 can be $-(CH_2)_7-CH_3$. In another embodiment, K^2 can be substituted or unsubstituted aryl. In still another embodiment, K^2 can be phenyl.

[0083] In Formulae (I), (II), and (III), as set forth above, the saccharide can be a monosaccharide, a disaccharide, an oligosaccharide, a polysaccharide, an N-acetylated derivative thereof, and an N-deacylated derivative thereof. In an exemplary embodiment, the saccharide is selected from the group consisting of:



[0084] In another exemplary embodiment, the saccharide is:



25 [0085] The invention also encompasses all pharmaceutically acceptable isomers, salts, hydrates, solvates, and prodrugs of each of the compounds described above. In addition, such compounds can exist in various isomeric and tautomeric forms, and all

such forms are meant to be included in the invention, along with pharmaceutically acceptable salts, hydrates, and solvates of such isomers and tautomers.

D. Methods of Making the Compositions

[0086] According to the invention, synthetic ganglioside compounds of formulae (I) (II) and (III) may be prepared using, unless otherwise indicated, conventional methods and protocols in chemistry and enzymology known in the art. For example, compounds of the invention may be prepared by synthetic and enzymatic processes as described in WO 03/017949 (published March 6, 2003) and WO 03/011879 (published February 13, 2003) which are herein incorporated by reference.

10 Compounds of the invention may be prepared by synthetic and enzymatic processes as outlined in Schemes 1-6 set forth below.

D1. Method of preparing the saccharide

[0087] The saccharide portion of the compounds of the invention may be prepared by any means known in the art including those methods described in U.S. Patents No. 5,922,577, 6,284,493 and 6,331,418, each of which is incorporated herein in its entirety by reference. Preferably, the saccharide portion of the compounds of the invention is prepared enzymatically whereby a specific enzyme may be used to affect transfer of a monosaccharide from a donor molecule to an acceptor molecule, each as defined herein.

20 [0088] More specifically, disaccharides, oligosaccharides and polysaccharides, as found in the synthetic ganglioside compounds of the invention, may be prepared biosynthetically by use of glycosyltransferases. Such glycosyltransferase reactions may be carried out in the presence of an organic solvent, such as, for example, methanol, ethanol, dimethylsulfoxide, isopropanol, tetrahydrofuran, chloroform, and the like, either singly or in combination. Alternatively, such glycosyltransferase reactions may be conducted in a biological medium *in vitro*, such as a biological buffer, a cell lysate, or on a chromatographic support, wherein the glycosyltransferase is immobilized on the chromatographic support and the other components of the reaction mixture are contacted with the glycosyltransferase by contacting the components with the chromatographic support in an aqueous medium.

25 [0089] Glycosyltransferase-mediated synthesis of saccharides found in synthetic ganglioside compounds of the invention may also be conducted *in vivo*. For example,

whole-cell expression systems may be used for glycosyltransferase-mediated synthesis. Cell types that may be used for expression of glycosyltransferases and concomitant production of saccharide structures include bacterial cells, yeast cells, and insect cells, as would be understood by one of skill in the art. The desired

5 saccharide product can be isolated from the cell in which it was synthesized by lysis of the cell, or by isolation of cell culture medium when using a cell that secretes the saccharide product into the culture medium. The saccharide product may then be purified by means described elsewhere herein, or it may be used without further purification in a lysate or cell culture medium.


10 [0090] As would be understood by one of skill in the art, the enzyme used may vary depending upon the monosaccharide to be transferred. Examples of suitable enzymes include, but are not limited to, glycosyltransferases, trans-sialidases, and sialyltransferases. The choice of glycosyltransferase(s) used in a given synthesis method of the invention will depend upon the identity of the acceptor and donor

15 molecules used as the starting material and the nature of the desired end product. A method of the invention can involve the use of more than one glycosyltransferase, where more than one saccharide is to be added. Multiple glycosyltransferase reactions can be carried out simultaneously, *i.e.*, in the same reaction mixture at the same time, or sequentially.

20 [0091] To obtain sufficient amounts of glycosyltransferase for large-scale *in vitro* reaction, a nucleic acid that encodes a glycosyltransferase can be cloned and expressed as a recombinant soluble enzyme by methods known to one of ordinary skill in the art. The expressed enzyme may then be purified by means known to one of ordinary skill in the art, or it may be used without further purification in a lysate or

25 cell culture medium.


26 [0092] By way of example, the saccharide moiety:




may be prepared by contacting an acceptor molecule containing a glucose (Glc) with a galactosyltransferase and a galactose (Gal) donor molecule to form:




which in turn can be contacted with a trans-sialidase and a NANA donor molecule to form:



5 which in turn can be contacted with a N-acetylated galactose (GalNAc)-transferase and a GalNAc donor molecule to form:



which in turn can be contacted with a galactosyltransferase and a galactose (Gal) donor molecule to form the desired saccharide:



10 [0093] If the acceptor is a ceramide, the enzymatic step is typically preceded by hydrolysis of the fatty acid moiety from the ceramide; a fatty acid moiety can be reattached after completion of the glycosyltransferase reaction. The initial monosaccharide may be added, depending on the desired end product, either a ceramide glucosyltransferase (EC 2.4.1.80, for glucosylceramide) or a ceramide galactosyltransferase (EC 2.4.1.45, for galactosylceramide). For review of glycosphingolipid biosynthesis, see, e.g., Ichikawa and Hirabayashi, *Trends Cell Biol.*, 8:198-202 (1998). Ceramide glucosyltransferases are available from various sources. For example, the human nucleotide sequence is known (GenBank Accession No. D50840; Ichikawa *et al.*, *Proc. Nat'l. Acad. Sci. USA*, 93:4638-4643 (1996)), so recombinant methods can be used to obtain the enzyme. The nucleotide sequence of the human ceramide galactosyltransferase also has been reported (GenBank Accession No. U62899; Kapitonov and Yu, *Biochem. Biophys. Res. Commun.*, 232: 449-453 (1997)), and thus the enzyme is easily obtainable. The acceptor used in these reactions can be any of N-acylsphingosine, sphingosine and dihydrosphingosine.

15 20 25 Suitable donor nucleotide sugars for the glycosyltransferase include UDP-Glc and CDP-Glc, while the galactosyltransferase typically uses UDP-Gal as a donor.

[0094] Methods of removing a fatty acid moiety from a glycosphingolipid are known to those of skill in the art. Standard carbohydrate and glycosphingolipid chemistry methodology can be employed, such as that described in, for example, Paulson *et al.*, *Carbohydrate Res.*, 137:39-62 (1985); Beith-Halahmi *et al.*, 5 *Carbohydrate Res.*, 5: 25-30 (1967); Alais and Veyrieries, *Carbohydrate Res.*, 207:11-31 (1990); Grudler and Schmidt, *Carbohydrate Res.*, 135:203-218 (1985); Ponpipom *et al.*, *Tetrahedron Lett.*, 1717-1720 (1978); Murase *et al.*, *Carbohydrate Res.*, 188:71-80 (1989); Kameyama *et al.*, *Carbohydrate Res.*, 193:c1-c5 (1989); Hasegawa *et al.*, *J. Carbohydrate Chem.*, 10:439-459 (1991); Schwarzmann and 10 Sandhoff, *Meth. Enzymol.*, 138:319-341 (1987); Guadino and Paulson, *J. Am. Chem. Soc.*, 116: 1149-1150 (1994) (including supplemental material, which is also incorporated herein by reference). For example, hydrolysis of the fatty acid moiety can be effected by base hydrolysis. Once the glycosylation reactions are completed, the same or a different fatty acid can be attached to the product of the glycosylation 15 reactions. Methods for coupling a fatty acid include those known in the art.


[0095] Another possible biosynthetic method for the synthesis of the saccharide portion of a compound of the invention is exemplified in Scheme 1 below. In a preferred embodiment, the acceptor molecule is non-immobilized. For example, the acceptor molecule may be free in solution or otherwise not associated with other 20 acceptor molecules.

[0096] Additional saccharide residues may be added to a compound of the invention without prior modification of the glycosylation pattern of the glycosphingolipid starting material. Alternatively, the invention provides methods of altering the glycosylation pattern of a glycosphingolipid prior to adding the additional 25 saccharide residues. If the starting glycosphingolipid does not provide a suitable acceptor for the glycosyltransferase which catalyzes a desired saccharide addition, one can modify the glycosphingolipid to include an acceptor by methods known to those of skill in the art. For example, to provide a suitable acceptor for a sialyltransferase, a suitable acceptor can be synthesized by using a 30 galactosyltransferase to attach a galactose residue to, for example, a GalNAc or other appropriate saccharide moiety that is linked to the glycosphingoid. In other embodiments, glycosphingoid-linked oligosaccharides can be first "trimmed," either in whole or in part, to expose either an acceptor for the sialyltransferase or a moiety to

which one or more appropriate residues can be added to obtain a suitable acceptor. Enzymes such as glycosyltransferases and endoglycosidases are useful for the attaching and trimming reactions.

[0097] Sialyltransferases and other glycosyltransferases can be used either alone or in conjunction with additional enzymes. For example, Figure 2 shows a schematic diagram of two pathways for synthesis of the ganglioside GD_2 starting from lactosylceramide. Each pathway involves the use of two different sialyltransferases (an $\alpha 2,3$ ST and an $\alpha 2,8$ ST), as well as a GalNAc transferase. In the preferred pathway, the fatty acid is removed from the lactosylceramide by treatment with base (Step 1). Acetylation is then performed (Step 2), after which a sialic acid is attached to the galactose residue in an $\alpha 2,3$ linkage by an $\alpha 2,3$ sialyltransferase (Step 3). The sialylation steps are performed, preferably in the presence of an organic solvent as described herein, thereby driving the reaction nearly to completion. A GalNAc residue is then added to the galactose in a $\beta 1,4$ linkage using a GalNAc transferase (Step 5). Finally, a fatty acid is added, e.g., by reaction with steryl chloride, to complete the ganglioside (Step 6).

SCHEME 1




D2. Method of Preparing Compounds of Formulae (I) – (III)


[0098] Compounds of the invention may be prepared by any means known in the art. Preferred synthetic pathways are illustrated in Schemes 2-5.

5


SCHEME 2




SCHEME 3



SCHEME 4



SCHEME 5



[0099] Once synthesized, the compounds of the invention may be isolated and purified by any means known in the art including, but not limited to, chromatography (e.g., thin, ion-exchange; column), filtration, membrane filtration (e.g., reverse osmotic membrane, nanfiltration), recrystallization, distillation, and the like.

[0100] A compound of the invention is useful in the field of neuroprotection. The term "neuroprotection" relates to any prophylaxis (pre-onset), treatment (on-set) and/or cure (post-onset) of indications resulting from the impairment or destruction of neuronal cells. Such indications include Parkinson's disease, ischemia, stroke, Alzheimer's, central nervous system disorders (e.g., spinal cord injury), multiple sclerosis, Huntington's disease, CABG, depression, anxiety, encephalitis, meningitis, amyotrophic lateral sclerosis, trauma, spinal cord injury, nerve injury, and nerve regeneration. A compound of the invention is also useful in the treatment of cancers.

in general, including liver, lung, colon, prostate, breast, pancreatic, and cancers of the brain, such as glioma and neuroblastoma. Further, a compound of the present invention is useful as an immunosuppressive and immunostimulatory agent, and has applications in organ transplantation, autoimmune disease, arthritis, Systemic Lupus Erythematosus, irritable bowel disease, radiation toxicity and inflammation, psoriasis, dermatitis, multiple sclerosis, trauma and sepsis.

5 [0101] A compound of the invention can be used to stimulate or suppress T-cells and B-cells, and can be used for antibody suppression or stimulation. Methods of stimulating and suppressing T-cells and B-cells is well-known in the art. Further, a compound of the invention may be used in a method to inhibit or activate membrane receptors, including G-protein coupled receptors, cell surface membrane receptor systems, and nuclear membrane receptors. A compound of the invention can further be used to treat type II diabetes and as an erythropoietin replacement.

10 [0102] A compound of the present invention is also useful as an inhibitor of platelet aggregation. Further, a compound of the present invention is useful in AIDS treatment, by inhibiting viral adhesion through G-protein coupled receptors, including CCRC5 and CXC4. A compound of the invention is also useful in the treatment of diseases such as Chagas disease, as well as diseases, disorders, and conditions described in U.S. Pat. Nos. 4,476,119, 4,593,091, 4,639,437, 4,707,469, 4,713,374, 15 4,716,223, 4,849,413, 4,940,694, 5,045,532, 5,135,921, 5,183,807, 5,190,925, 5,210,185, 5,218,094, 5,229,373, 5,260,464, 5,264,424, 5,350,841, 5,424,294, 20 5,484,775, 5,519,007, 5,521,164, 5,523,294, 5,677,285, 5,792,858, 5,795,869, and 5,849,717, each of which is incorporated by reference herein.

25 [0103] One possible mechanism of action of a compound of the invention is to stimulate nerve growth factors. Another possible mechanism of action of a compound of the invention is to inhibit growth of cancer cells, and in particular, neuroblastoma cells. For example, it has been shown that administration of ganglioside GM3 to murine neuroblastoma cells can inhibit the growth of the neuroblastoma cells (Zhang *et al.*, *Anticancer Res.*, 15:661-666 (1995)). Ganglioside and ganglioside-like 30 compounds of the present invention can be used in a similar inhibitory capacity.

[0104] According to the invention, isolated and purified compounds of the invention for use in the field of neuroprotection or cancer treatment are of an

acceptable purity level. As would be understood by one of skill in the art, acceptable purity levels would depend upon the particular application. The compounds of the invention may be purified to levels ranging from about 80-100% pure, preferably, from about 90-100% pure, and more preferably about 95-100% pure.

5 **E. Pharmaceutical Compositions**

[0105] The invention further provides a pharmaceutical composition comprising at least one synthetic ganglioside compound of formulae (I), (II) and (III), each as set forth above, and a pharmaceutically acceptable carrier. Mixtures of synthetic gangliosides of the invention are also contemplated for use in pharmaceutical compositions.

[0106] Pharmaceutical compositions of the invention may be prepared for storage or administration by any means known in the art. For example, a pharmaceutical composition of the invention may be prepared by mixing a compound of the invention, preferably having a desired degree of purity, with a pharmaceutically or physiologically acceptable carriers or agent. The amount of active ingredient in these compositions is such that a suitable dosage in the range indicated is obtained.

[0107] A pharmaceutically acceptable carrier or agent may be any such carrier or agent known in the art. See, for example, in Gennaro *et al.*, Remington's Pharmaceutical Sciences, Mack Publishing Co., (1985). The pharmaceutical composition of the invention may further include a binder (e.g., acacia, corn starch or gelatin), an excipient (e.g., microcrystalline cellulose), a disintegrating agent (e.g., corn starch or alginic acid), a lubricant (e.g., magnesium stearate), a sweetening agent (e.g., sucrose or lactose), a buffer (e.g., phosphate, citrate, acetate and other organic acid salts), an antioxidant (e.g., ascorbic acid), a low molecular weight (less than about ten residues) peptide (e.g. polyarginine), a protein (e.g., serum albumin, gelatin, or immunoglobulins), a hydrophilic polymer (e.g., polyvinylpyrrolidinone), an amino acid (e.g., glycine, glutamic acid, aspartic acid, or arginine), a monosaccharide, a disaccharide, and other carbohydrates (e.g. cellulose or its derivatives, glucose, mannose or dextrans), a chelating agent (e.g., EDTA), sugar alcohol (e.g., mannitol or sorbitol), a counterion (e.g., sodium) and/or nonionic surfactants such as TWEEN, Pluronics or polyethyleneglycol. Additional acceptable adjuvants include those well

known in the pharmaceutical field, and as described, for example, in Gennaro *et al.*, Remington's Pharmaceutical Sciences, Mack Publishing Co., (1985).

[0108] A compound or a pharmaceutical composition of the invention may be administered in solid or liquid form depending upon the desired application. Thus, a compound or pharmaceutical composition of the invention may be administered in solid form such as, for example, tablets, capsules, suppositories, in liquid form such as, for example, elixirs for oral administration, sterile solutions, sterile suspensions or injectable administration, and the like, or incorporated into shaped articles. A compound or a pharmaceutical composition of the invention may also be administered as sustained release and timed release formulations. Other modes of administration of a compound or composition of the invention include, but not limited to, implantable medical devices (e.g., stents), inhalable formulations, sprays, transdermal, liposomes, gels, intracranial, and intrathecal.

[0109] A compound or pharmaceutical composition of the invention, especially when administered in capsule form, may also contain a liquid carrier such as, for example, water, saline, or a fatty oil. Other materials of various types may be used as coatings or as modifiers of the physical form of the compound or pharmaceutical composition. For example, dissolution or suspension of the active compound of the invention in a vehicle such as an oil or a synthetic fatty vehicle like ethyl oleate, or into a liposome may be desired.

[0110] According to the invention, such materials as well as compounds of the invention are nontoxic to the recipients at the dosages and concentrations employed, *i.e.* are pharmaceutically acceptable.

[0111] In general, a compound of the invention, alone or as part of a pharmaceutical composition as described herein, may be used as a diagnostic or therapeutic agent for the prevention and/or treatment of disorders of the nervous system including neurological diseases such as, for example, Parkinson's disease, CABG, Alzheimer's Disease, and stroke. Further, a compound of the invention, alone or as part of a pharmaceutical composition as described herein, may be used as a therapeutic agent for the treatment of certain types of cancer, including neuroblastoma.

[0112] Compounds and pharmaceutical compositions of the invention are suitable for use alone or as part of a multi-component treatment regimen in combination with other therapeutic or diagnostic agents such as, for example, other synthetic gangliosides of the invention, natural gangliosides, other synthetic gangliosides, anti-inflammatory compounds, analgesics, other neurotrophic factors (e.g., growth factors). Coadministered compounds and agents may act in a synergistic fashion to enhance the neuroprotective activity of the compound of the invention.

[0113] The compounds and pharmaceutical compositions of the invention may be utilized *in vivo*, ordinarily in mammals such as primates, such as humans, sheep, 10 horses, cattle, pigs, dogs, cats, rats and mice, or *in vitro*. The biological properties, as described above, of the compounds of the invention can be readily characterized by methods that are well known in the art including, for example, *in vitro* screening protocols and *in vivo* studies to evaluate the neuroprotective activity of the tested compound or pharmaceutical composition.

[0114] Subjects (animals or humans), preferably mammalian, in need of treatment may be administered a therapeutically effective amount, *i.e.*, a dosage that will provide optimal efficacy, of a compound of the invention, alone or as part of pharmaceutical composition. As would be recognized by those of skill in the art, a "therapeutically effective amount" and mode of administration will vary from subject 15 to subject and thus will be determined on a case by case basis. Factors to be considered include, but are not limited to, the subject (*e.g.* mammal) being treated, its sex, weight, diet, concurrent medication, overall clinical condition, the particular compounds employed, and the specific use for which these compounds are employed. Therapeutically effective amounts or dosages may be determined by either *in vitro* or 20 *in vivo* methods. In general, a "therapeutically effective amount" of a compound or composition is an amount that will result in the prophylaxis, treatment or cure of neuronal cell disorders. For example, a therapeutically effective amount of a compound or composition of the invention in the prophylaxis, treatment or cure of Parkinson's disease will be that amount that results in slower progression of the 25 disease and/or development of motor skills. A therapeutically effective amount of a compound or composition of the invention in the prophylaxis, treatment or cure of Alzheimer's disease will be that amount that results in, for example, improvement of the subject's memory. A therapeutically effective amount of a compound or 30

composition of the invention in the prophylaxis, treatment or cure of the lasting effects of eschemia/stroke will be that amount that results in, for example, reduction of loss of neurological function (e.g., speech, motor, etc.) and/or improvement of sympathetic or parasympathetic pathways.

- 5 [0115] Modes of administration include those known in the art including, but not limited to, oral, injection, intravenous (bolus and/or infusion), subcutaneous, intramuscular, colonic, rectal, nasal and intraperitoneal administration. Preferably, compounds of the invention, alone or as part of a pharmaceutical composition are taken orally.
- 10 [0116] For injection by hypodermic needle, it may be assumed the dosage is delivered into the body's fluids. For other routes of administration, the absorption efficiency may be individually determined for each compound of the invention by methods well known in pharmacology. Accordingly, as would be understood by one of skill in the art, it may be necessary for the therapist to titer the dosage and modify 15 the route of administration as required to obtain the optimal therapeutic effect. The determination of effective dosage levels, that is, the dosage levels necessary to achieve the desired result, will be within the ambit of one skilled in the art. Typically, a compound of the invention is administered at lower dosage levels, with dosage levels being increased until the desired effect is achieved.
- 20 [0117] A typical dosage might range from about 0.1 mg/kg to about 1000 mg/kg, preferably from 0.1 mg/kg to about 100 mg/kg, more preferably from about 0.1 mg/kg to about 30 mg/kg, more preferably from about 0.1 mg/kg to about 10 mg/kg, and more preferably 0.1 mg/kg to about 3 mg/kg. Advantageously, the compounds of the invention, alone or as part of a pharmaceutical composition, may be administered 25 several times daily, and other dosage regimens may also be useful. A compound of the invention may be administered on a regimen in a single or multidose (e.g. 2 to 4 divided daily doses) and/or continuous infusion.
- 30 [0118] A compound of the invention, alone or as part of a pharmaceutical composition, for administration may be sterilized prior to administration. Sterility may be readily accomplished by filtration through sterile membranes such as 0.2 micron membranes, or by other conventional methods. A compound of the invention, alone or as part of a pharmaceutical composition, typically may be stored in

lyophilized form or as an aqueous solution. pH may be a factor for certain modes of administration. In such instances, the pH typically will range between about 2-10, preferably, between about 5-8, more preferably 6.5-7.5, *i.e.*, physiological pH.

F. Methods of Using the Compositions in Screening Protocols

5 [0119] The compounds and pharmaceutical compositions of the invention may be utilized *in vivo*, ordinarily in mammals such as primates, such as humans, sheep, horses, cattle, pigs, dogs, cats, rats and mice, or *in vitro*. The effectiveness of the compounds of the invention as neuroprotective agents may be determined using screening protocols known in the art. For example, the biological properties, as
10 described above, of the compounds of the invention can be readily characterized by methods that are well known in the art including, for example, *in vitro* screening protocols (e.g. cell culture (MPTP (rat ventral mesophenthalic cells), NMDA (mouse primary cortical neurons), ceramide (neuroblastoma-human)), CACO-2 (oral absorption), RBC lysis) and *in vivo* studies (e.g. mouse and primate MPTP toxicity
15 studies (IP, IV, and/or oral) for effectiveness in the treatment of Parkinson's, rat Stoke studies for effectiveness for treatment of neural damage due to stroke or CABG, and dog studies for treatment of CABG) to evaluate neuroprotective efficacy.


20 [0120] In the cell based assays, as described herein, the compounds of the invention exhibited 50-100% greater neuroprotective activity at lower concentrations ranging between about 0.1 to about 1 μ M.

25 [0121] The invention is now described with reference to the following Example. This Example is provided for the purpose of illustration only and the invention should in no way be construed as being limited to this Example, but rather should be construed to encompass any and all variations which become evident as a result of the teaching provided herein.

30 [0122] It should be understood that the foregoing discussion and examples merely present a detailed description of certain preferred embodiments. It will be apparent to those of ordinary skill in the art that various modifications and equivalents can be made without departing from the spirit and scope of the invention. All the patents, journal articles and other documents discussed or cited above are herein incorporated in their entirety by reference.


WHAT IS CLAIMED IS:

1 1. A compound having a structure according to Formula I:



3 wherein

4 X² is a member selected from




7 wherein

8 R¹, R², R³, R⁴, and R⁵ are members independently selected from
9 substituted or unsubstituted alkyl, substituted or unsubstituted
10 aryl, substituted or unsubstituted heteroaryl, substituted or
11 unsubstituted arylalkyl, and substituted or unsubstituted
12 heteroarylalkyl;

13 Z² is a member selected from substituted or unsubstituted alkenyl,
14 substituted or unsubstituted pyridinyl, and substituted or
15 unsubstituted phenyl;

16 with the proviso that when R¹ is -(CH₂)₁₆-CH₃, then Z² is not
17 unsubstituted pyridinyl,


18



1

2. The compound according to claim 1, wherein X² is

2



3

R¹ is substituted or unsubstituted alkyl.

1

3. The compound according to claim 2, wherein R¹ is a substituted or unsubstituted C₈-C₂₀ alkyl moiety.

1

4. The compound according to claim 2, wherein R¹ is haloalkyl.

1

5. The compound according to claim 4, wherein R¹ is a member selected from chloromethyl and dichloromethyl.

1

6. A pharmaceutical composition of claim 1 and a pharmaceutically acceptable carrier.

1

7. A method for the prevention or treatment of a disorder of the nervous system in an animal or human comprising the step of administering to an animal or human in need thereof a therapeutically effective amount of the compound of claim 1.

1

8. The method of claim 7, wherein said disorder of the nervous system is selected from the group consisting of Parkinson's disease, ischemia, stroke, Alzheimer's disease, depression, anxiety, encephalitis, meningitis, amyotrophic lateral sclerosis, trauma, spinal cord injury, nerve injury, and nerve regeneration.

1 9. A method for the treatment of a glioma in a human comprising
2 the step of administering to the human in need thereof a therapeutically effective
3 amount of the compound of claim 1.


1 10. A method of synthesizing a synthetic ganglioside compound of
2 claim 1, wherein the steps of synthesis of the saccharide moiety comprise:
3 contacting an acceptor molecule comprising a sphingoid moiety and a
4 glucose (Glc) with a galactosyltransferase enzyme and a galactose (Gal) donor
5 molecule to form:




7 contacting the




9 9 with a transsialidase enzyme and a sialic acid (NANA) donor
10 10 molecule to form:




12 12 contacting the




14 14 with a N-acetyl galactose (GalNAc)-transferase enzyme and a
15 15 GalNAc donor molecule to form:




17 17 contacting the



19 with a galactosyltransferase enzyme and a galactose (Gal)
20 donor molecule to form:




22 contacting the





24 with a fatty acid moiety under conditions sufficient to form a
25 ganglioside.

1 11. A compound having a structure according to Formula II:



3 wherein

4 X³ is a member selected from



7 wherein

8 R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ are members independently selected from
9 substituted or unsubstituted alkyl, substituted or unsubstituted
10 aryl, substituted or unsubstituted heteroaryl, substituted or

13 J¹ is -NR¹⁵R¹⁶

14 **wherein**

15 R¹⁵ and R¹⁶ are members independently selected from
16 substituted or unsubstituted alkyl; and


17 K¹ is a member selected from substituted or unsubstituted aryl and
18 substituted or unsubstituted heteroaryl.

12. The compound according to claim 11, wherein at least one
2 member selected from R¹⁵ and R¹⁶ is -(CH₂)₇-CH₃.

1 13. The compound according to claim 11, wherein K¹ is substituted
2 or unsubstituted aryl.

1 14. The compound according to claim 13, wherein K¹ is substituted
2 or unsubstituted phenyl.

15. The compound according to claim 11, wherein X^3 is



3 R^{10} is substituted or unsubstituted alkyl.

1 **16.** The compound according to claim 15, wherein R¹⁰ is a
2 substituted or unsubstituted alkyl moiety.

17. The compound according to claim 15, wherein R^{10} is haloalkyl.

1 18. The compound according to claim 17, wherein R¹⁰ is a member
2 selected from chloromethyl and dichloromethyl.

1 **19.** A pharmaceutical composition of claim 11 and a
2 pharmaceutically acceptable carrier.

1 **20.** A method for the prevention or treatment of a disorder of the
2 nervous system in an animal or human comprising the step of administering to an
3 animal or human in need thereof a therapeutically effective amount of the compound
4 of claim 11.


1 **21.** The method of claim 20, wherein said disorder of the nervous
2 system is selected from the group consisting of Parkinson's disease, ischemia, stroke,
3 Alzheimer's disease, depression, anxiety, encephalitis, meningitis, amyotrophic lateral
4 sclerosis, trauma, spinal cord injury, nerve injury, and nerve regeneration.

1 **22.** A method for the treatment of a glioma in a human comprising
2 the step of administering to the human in need thereof a therapeutically effective
3 amount of the compound of claim 11.

1 **23.** A method of synthesizing a synthetic ganglioside compound of
2 claim 11, wherein the steps of synthesis of the saccharide moiety comprise:
3 contacting an acceptor molecule comprising a sphingoid moiety and a
4 glucose (Glc) with a galactosyltransferase enzyme and a galactose (Gal) donor
5 molecule to form:




7 contacting the




9 with a transsialidase enzyme and a sialic acid (NANA) donor
10 molecule to form:




12 contacting the




13
14 with a N-acetyl galactose (GalNAc)-transferase enzyme and a
15 GalNAc donor molecule to form:




16
17 contacting the



18
19 with a galactosyltransferase enzyme and a galactose (Gal)
20 donor molecule to form:




21
22 contacting the



23
24 with a fatty acid moiety under conditions sufficient to form a
25 ganglioside.

1
24. A compound having a structure according to Formula III:



2
3 wherein

4 X^4 is substituted or unsubstituted alkyl, $-C(=M^2)R^{20}$, $-C(=M^2)-Q^2-R^{20}$,
5 $-SO_2R^{20}$;
6 wherein R^{20} is a member selected from substituted or
7 unsubstituted alkyl and substituted or unsubstituted
8 heteroalkyl;
9 M^2 and Q^2 are members independently selected from O, NR²¹
10 and S;
11 wherein
12 R^{21} are members independently selected from H,
13 substituted or unsubstituted alkyl, substituted or
14 unsubstituted heteroalkyl, substituted or
15 unsubstituted aryl, substituted or unsubstituted
16 heteroaryl, substituted or unsubstituted
17 heterocycloalkyl; and
18 A^1 and A^2 are members independently selected from H, substituted or
19 unsubstituted alkyl, and substituted or unsubstituted
20 heteroalkyl;
21 K^2 is a member selected from substituted or unsubstituted alkyl,
22 substituted or unsubstituted aryl, substituted or unsubstituted
23 heteroaryl, substituted or unsubstituted arylalkyl, and
24 substituted or unsubstituted heteroarylalkyl;
25 with the proviso that if A^1 is $-(CH_2)_7-CH_3$, A^2 is $-(CH_2)_7-CH_3$, X^4 is
26 $-C(=O)R^{20}$, and R^{20} is $-(CH_2)_{16}-CH_3$, then K^2 is not
27 unsubstituted phenyl.

1 **25.** The compound according to claim 24, wherein X^4 is
2 $-C(=O)R^{20}$, and R^{20} is substituted or unsubstituted alkyl.

1 **26.** The compound according to claim 25, wherein X^4 is



1 **27.** The compound according to claim 24, wherein A¹ and A² are
2 independently selected from substituted or unsubstituted alkyl.

1 **28.** The compound according to claim 24, wherein A¹ and A² are
2 -(CH₂)₇-CH₃.

1 **29.** The compound according to claim 24, wherein K² is substituted
2 or unsubstituted aryl.

1 **30.** The compound according to claim 29, wherein K² is phenyl.

1 **31.** A pharmaceutical composition of claim 24 and a
2 pharmaceutically acceptable carrier.

1 **32.** A method for the prevention or treatment of a disorder of the
2 nervous system in an animal or human comprising the step of administering to an
3 animal or human in need thereof a therapeutically effective amount of the compound
4 of claim 24.

1 **33.** The method of claim 32, wherein said disorder of the nervous
2 system is selected from the group consisting of Parkinson's disease, ischemia, stroke,
3 Alzheimer's disease, depression, anxiety, encephalitis, meningitis, amyotrophic lateral
4 sclerosis, trauma, spinal cord injury, nerve injury, and nerve regeneration.

1 **34.** A method for the treatment of a glioma in a human comprising
2 the step of administering to the human in need thereof a therapeutically effective
3 amount of the compound of claim 24.

1 **35.** A method of synthesizing a synthetic ganglioside compound of
2 claim 24, wherein the steps of synthesis of the saccharide moiety comprise:
3 contacting an acceptor molecule comprising a sphingoid moiety and a
4 glucose (Glc) with a galactosyltransferase enzyme and a galactose (Gal) donor
5 molecule to form:


6



7

contacting the


8



9

10 with a transsialidase enzyme and a sialic acid (NANA) donor molecule to form:


11



12

contacting the


13



14

15 with a N-acetyl galactose (GalNAc)-transferase enzyme and a GalNAc donor molecule to form:


16



17

contacting the


18



19

20 with a galactosyltransferase enzyme and a galactose (Gal) donor molecule to form:


21



22

contacting the

23



24

25 with a fatty acid moiety under conditions sufficient to form a ganglioside.

1

GLYCOLIPIDS

2

ABSTRACT OF THE DISCLOSURE

3 Novel synthetic gangliosides and pharmaceutical compositions containing such
4 synthetic gangliosides are described. Methods of making the novel synthetic
5 ganglioside compounds and compositions as well as their use in the field of
6 neuroprotection is also described.

I-SF/7167128.1

Application Data Sheet

Application Information

Application number::

Filing Date:: 11/09/04

Application Type:: Provisional

Subject Matter:: Utility

Suggested classification::

Suggested Group Art Unit::

CD-ROM or CD-R??::

Number of CD disks::

Number of copies of CDs::

Sequence Submission::

Computer Readable Form (CRF)?::

Number of copies of CRF::

Title:: GLYCOLIPIDS

Attorney Docket Number:: 40853-01-5157-PR

Request for Early Publication:: No

Request for Non-Publication:: No

Suggested Drawing Figure::

Total Drawing Sheets::

Small Entity?:: Yes

Latin name::

Variety denomination name::

Petition included?:: No

Petition Type::

Licensed US Govt. Agency::

Contract or Grant Numbers One::

Secrecy Order in Parent Appl.?:: No

Applicant Information

Applicant Authority Type:: Inventor
Primary Citizenship Country:: US
Status:: Full Capacity
Given Name:: Shawn
Middle Name::
Family Name:: DeFrees
Name Suffix::
City of Residence:: North Wales
State or Province of Residence:: PA
Country of Residence:: US
Street of Mailing Address:: 126 Filly Drive
City of Mailing Address:: North Wales
State or Province of mailing address:: PA
Country of mailing address:: US
Postal or Zip Code of mailing address:: 19454

Applicant Authority Type:: Inventor
Primary Citizenship Country:: US / Peoples Republic of China
Status:: Full Capacity
Given Name:: Zhi-Guang
Middle Name::
Family Name:: Wang
Name Suffix::
City of Residence:: Dresher
State or Province of Residence:: PA
Country of Residence:: US
Street of Mailing Address:: 1473 Golden Drive
City of Mailing Address:: Dresher
State or Province of mailing address:: PA
Country of mailing address:: US

Postal or Zip Code of mailing address:: 19015

Correspondence Information

Correspondence Customer Number:: 43850

Representative Information

Representative Customer Number:: 43850

Domestic Priority Information

Application:: Continuity Type:: Parent Application:: Parent Filing Date::

Foreign Priority Information

Country:: Application number:: Filing Date::

Assignee Information

Assignee Name::

Street of mailing address::

City of mailing address::

State or Province of mailing address::

Country of mailing address::

Postal or Zip Code of mailing address::